| Source: |
| Type: |
| Tumor cell cycle arrest refers to the process by which cancer cells stop progressing through the cell cycle, which is the series of phases that a cell goes through to divide and replicate. This arrest can occur at various checkpoints in the cell cycle, including the G1, S, G2, and M phases.
S, G1, G2, and M are the four phases of mitosis. |
| 8518- | MAG, | Magnolol suppresses the proliferation and invasion of cholangiocarcinoma cells via inhibiting the NF-κB signaling pathway |
| - | in-vitro, | CCA, | NA |
| 8497- | MAG, | Magnolol induces apoptosis in MCF-7 human breast cancer cells through G2/M phase arrest and caspase-independent pathway |
| - | in-vitro, | BC, | MCF7 |
| 8498- | MAG, | Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells |
| - | in-vitro, | Kidney, | 786-O | - | in-vitro, | RCC, | OS-RC-2 | - | in-vitro, | Nor, | HK-2 |
| 8505- | MAG, | Role of magnolol in gastrointestinal cancers: Recent trends and future perspectives |
| - | Review, | GC, | NA |
| 8516- | MAG, | Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma |
| - | in-vitro, | Melanoma, | NA |
| 4533- | MAG, | Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways |
| - | in-vitro, | GC, | SGC-7901 |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4515- | MAG, | Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight |
| - | Review, | Var, | NA |
| 4516- | MAG, | Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models |
| - | in-vivo, | NSCLC, | NA |
| 4536- | MAG, | Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | CRC, | COLO205 |
| 4537- | MAG, | Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action |
| - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | A431 |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 8561- | Matr, | Matrine triggers colon cancer cell apoptosis and G0/G1 cell cycle arrest via mediation of microRNA-22 |
| - | in-vitro, | Colon, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 8567- | Matr, | Matrine induces apoptosis in multiple colorectal cancer cell lines in vitro and inhibits tumour growth with minimum side effects in vivo via Bcl-2 and caspase-3 |
| - | vitro+vivo, | CRC, | NA |
| 8542- | Matr, | Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival Signaling |
| - | vitro+vivo, | Lung, | A549 |
| 8560- | Matr, | Matrine: A Promising Natural Product With Various Pharmacological Activities |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Var, | NA |
| 8554- | Matr, | Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation |
| - | in-vitro, | PC, | Capan1 | - | in-vitro, | PC, | MIA PaCa-2 |
| 8553- | Matr, | Research progress on the pharmacological effects of matrine |
| - | Review, | Nor, | NA |
| 8923- | MBS, | Novel molecular, cytotoxical, and immunological study on promising and selective anticancer activity of Mung bean sprouts |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 |
| 8627- | MBZ, | Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8632- | MBZ, | Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo |
| - | vitro+vivo, | Lung, | NA |
| 8634- | MBZ, | Rad, | Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer |
| - | vitro+vivo, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 8635- | MBZ, | The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma |
| - | vitro+vivo, | Melanoma, | NA |
| 8641- | MBZ, | ONC201, | The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline glioma |
| - | in-vitro, | GBM, | NA |
| 8643- | MBZ, | Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | SUM159 |
| 8653- | MBZ, | Cisplatin, | Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC) |
| - | in-vitro, | HNSCC, | CAL27 | - | in-vitro, | HNSCC, | SCC-154 |
| 8650- | MBZ, | Autophagy Is a Potential Target for Enhancing the Anti-Angiogenic Effect of Mebendazole in Endothelial Cells |
| - | in-vitro, | Var, | NA |
| 8649- | MBZ, | Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01) |
| - | in-vitro, | GC, | AGP01 |
| 8786- | mCHEMO, | Metronomic chemotherapy in cancer treatment: new wine in an old bottle |
| - | Review, | Var, | NA |
| 8821- | MCP, | Rad, | Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 8822- | MCP, | Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3 |
| - | vitro+vivo, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | J82 |
| 8715- | MeJa, | Methyl jasmonate decreases membrane fluidity and induces apoptosis via tumor necrosis factor receptor 1 in breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-453 | - | in-vitro, | BC, | MCF-10AT |
| 8717- | MeJa, | Methyl jasmonate induces apoptosis and pro-apoptotic autophagy via the ROS pathway in human non-small cell lung cancer |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | H157 | - | in-vitro, | Lung, | H1792 |
| 8720- | MeJa, | Methyl jasmonate downregulates expression of proliferating cell nuclear antigen and induces apoptosis in human neuroblastoma cell lines |
| - | in-vitro, | neuroblastoma, | SK-N-SH |
| 8718- | MeJa, | Methyl jasmonate induces apoptosis through induction of Bax/Bcl-XS and activation of caspase-3 via ROS production in A549 cells |
| - | in-vitro, | Lung, | A549 |
| 8757- | MeSA, | Methylseleninic acid (MSA) inhibits 17β-estradiol-induced cell growth in breast cancer T47D cells via enhancement of the antioxidative thioredoxin/ thioredoxin reductase system |
| - | in-vitro, | BC, | T47D |
| 8751- | MeSA, | PacT, | Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 8742- | MeSA, | Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells |
| - | in-vitro, | Pca, | DU145 |
| 8759- | MeSA, | Methylseleninic acid induces apoptosis of human bladder cancer cells through the ROS-mediated mitochondrial pathway |
| - | in-vitro, | Bladder, | J82 | - | in-vitro, | CRC, | T24/HTB-9 |
| 8764- | MeSA, | Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition |
| - | in-vitro, | Lung, | A549 |
| 2384- | MET, | Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vivo, | NA, | NA | - | in-vitro, | Thyroid, | TPC-1 |
| 5803- | MET, | carbop, | Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | SKOV3 |
| 5795- | MET, | Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Diabetic, | NA |
| 496- | MF, | Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | ZR-75-1 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 524- | MF, | Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs) |
| - | vitro+vivo, | PC, | MS-1 | - | vitro+vivo, | PC, | HUVECs |
| 487- | MF, | Extremely Low-Frequency Electromagnetic Fields Cause G1 Phase Arrest through the Activation of the ATM-Chk2-p21 Pathway |
| - | in-vitro, | NMSC, | HaCaT |
| 497- | MF, | In Vitro and in Vivo Study of the Effect of Osteogenic Pulsed Electromagnetic Fields on Breast and Lung Cancer Cells |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | Lung, | A549 |
| 508- | MF, | doxoR, | Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line |
| - | in-vitro, | BC, | MCF7 |
| 4353- | MF, | Chemo, | Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:322 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid